OptheaCKDXF 3-Year RORE % is -23.63 as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,293 Biotechnology companies, Opthea ranks worse than 61.02% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Opthea's 3-Year RORE % for the quarter that ended in Jun. 2025 was -23.63%.
The industry rank for Opthea's 3-Year RORE % or its related term are showing as below:
CKDXF's 3-Year RORE % is ranked worse than 61.02% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs CKDXF: -23.63
Opthea (OTCPK:CKDXF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Opthea 3-Year RORE % Related Terms
Opthea 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Opthea's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CKDXF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Opthea's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opthea 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opthea's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Opthea's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.
Opthea (CKDXF) has a 3-Year RORE % of -23.63 as of Jun. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Opthea and its competitors. According to the industry distribution chart, Opthea ranks #789 out of 1293 companies in the Biotechnology industry, placing it in the top 61%.
Is Opthea's 3-Year RORE % too high?
Opthea's current 3-Year RORE % is -23.63. Based on the distribution chart, Opthea ranks #789 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint.
How does Opthea's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Opthea ranks #789 out of 1293 companies for 3-Year RORE %. This places Opthea in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Opthea and its competitors. Opthea's current 3-Year RORE % is -23.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opthea stock overvalued right now?
Opthea (CKDXF) has a current 3-Year RORE % of -23.63. The current 3-Year RORE % is -23.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Opthea (CKDXF), the current 3-Year RORE % is -23.63 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKDXF has been successfully added to your 